Fatal pancreatitis occurred in a patient with refractory CD30+ anaplastic large cell lymphoma after brentuximab vedotin treatment

Abstract

Brentuximab vedotin is a quite safe and effective targeted drug for patients with CD30+ anaplastic large cell lymphoma, but we still need to be careful some rare and severe adverse events after brentuximab vedotin treatment. Here we present a 32-year-old Asian male with CD30+ anaplastic large cell lymphoma who received brentuximab vedotin treatment and admitted to our ward 12 days later because of severe pancreatitis. Although intensive care had given, he still expired as a result of acute pancreatitis with multiple organs failure. Unintended targeting of BV to the pancreatic cells is a possible etiology of such acute pancreatitis. Severe epigastric pain in patients after Brentuximab vedotin may be a warning of severe pancreatitis and more intensive care should be considered.

Keywords

• Pancreatitis
• Anti-CD30
• Brentuximab vedotin
• Anaplastic large cell lymphoma